Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04925193 · OUTCOME

Duration of Response

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma · Source last updated 2026-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years

What was measured

To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy

Analysis population: The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. This analysis was preplanned in the study protocol. Analysis of the secondary endpoint of duration of response will be performed on the Intent-to-treat (ITT) population, which will include all subjects who have been enrolled for the study.

Groups in this outcome

Group 1

Group 1: * Selinexor 60 mg PO days 1, 8, 15 * Pomalidomide 4 mg PO on days 1-21 * Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 * 28 day treatment cycles Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Pomalidomide: Oral Table Dexamethasone: Oral tablet or injection

Group 2

Group 2: Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Daratumumab: Injection Dexamethasone: Oral tablet or injection

Group 3

Group 3: * Selinexor 80 mg PO days 1, 8, 15 * Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. * Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 * 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Carfilzomib: Injection Dexamethasone: Oral tablet or injection

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group 13
Group 26
Group 39

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group 13.08Not reported0.76.7Not reported
Group 27.9Not reported3.210.5Not reported
Group 311.9Not reported4.616.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.7
        upper Limit
        6.7
        value
        3.08
      2. group Id
        OG001
        lower Limit
        3.2
        upper Limit
        10.5
        value
        7.9
      3. group Id
        OG002
        lower Limit
        4.6
        upper Limit
        16.1
        value
        11.9
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      6
    3. group Id
      OG002
      value
      9
    units
    Participants
description
To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy
dispersion Type
95% Confidence Interval
groups
  1. description
    Group 1: * Selinexor 60 mg PO days 1, 8, 15 * Pomalidomide 4 mg PO on days 1-21 * Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 * 28 day treatment cycles Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Pomalidomide: Oral Table Dexamethasone: Oral tablet or injection
    id
    OG000
    title
    Group 1
  2. description
    Group 2: Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Daratumumab: Injection Dexamethasone: Oral tablet or injection
    id
    OG001
    title
    Group 2
  3. description
    Group 3: * Selinexor 80 mg PO days 1, 8, 15 * Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. * Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 * 28 day treatment cycle Selinexor: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1). Carfilzomib: Injection Dexamethasone: Oral tablet or injection
    id
    OG002
    title
    Group 3
param Type
MEDIAN
population Description
The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. This analysis was preplanned in the study protocol. Analysis of the secondary endpoint of duration of response will be performed on the Intent-to-treat (ITT) population, which will include all subjects who have been enrolled for the study.
reporting Status
POSTED
time Frame
End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years
title
Duration of Response
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice